专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070029485A1 Method of operating an avalanche photodiode for reducing gain normalized dark current 有权
标题翻译：操作雪崩光电二极管以减少增益归一化暗电流的方法
公开(公告)号：US20070029485A1
公开(公告)日：2007-02-08
申请号：US11196100
申请日：2005-08-03
申请人： Jeffrey Beck , Pradip Mitra , Chang-Feng Wan , Michael Kinch
发明人： Jeffrey Beck , Pradip Mitra , Chang-Feng Wan , Michael Kinch
IPC分类号： H01L31/00 , H01L31/0296
CPC分类号： H01L31/02027 , H01L31/0296 , H01L31/02966 , H01L31/1032 , H01L31/105 , H01L31/107
摘要： An avalanche photodiode is operated in avalanche mode at a selected reverse bias that achieves high gain and a reduced gain normalized dark current.
摘要翻译：雪崩光电二极管以选择的反向偏置在雪崩模式下操作，其实现高增益和减小的标准化暗电流。

2. 发明申请

US20080187528A1 ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS 有权
标题翻译： ANTI-TSG101抗体及其用于治疗病毒感染的用途
公开(公告)号：US20080187528A1
公开(公告)日：2008-08-07
申请号：US11940714
申请日：2007-11-15
申请人： Limin Li , Michael Kinch , Michael Goldblatt
发明人： Limin Li , Michael Kinch , Michael Goldblatt
IPC分类号： A61K39/00 , C07K16/00
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/18 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/76
摘要： The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
摘要翻译：本发明提供了结合TSG101的C-末端区域的抗体。本发明还提供了使用TSG101抗体治疗病毒感染（包括HIV和埃博拉病毒感染）的方法。

3. 发明申请

US20060121043A1 Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections 审中-公开
标题翻译：使用EphA2和EphrinA1调节剂治疗和预防感染
公开(公告)号：US20060121043A1
公开(公告)日：2006-06-08
申请号：US11259266
申请日：2005-10-27
申请人： Michael Kinch , Kelly Carles-Kinch
发明人： Michael Kinch , Kelly Carles-Kinch
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505 , Y02A50/403 , Y02A50/41
摘要： The present invention provides methods and compositions designed for the treatment, management, and/or amelioration of an infection, in particular an intracellular pathogen infection, such as a viral, bacterial, protozoa or fungal infection. In particular, the present invention provides methods for treating, managing, preventing and/or ameliorating an infection where the expression of EphA2 is upregulated in infected cells (e.g., infected epithelial cells), said methods comprising administering to a subject an effective amount of one or more EphA2/EphrinA1 Modulators. In accordance with the present invention, such methods may also comprise the administration of one or more therapies other than an EphA2/EphrinA1 Modulator. The present invention also provides pharmaceutical compositions comprising EphA2/EphrinA1 Modulators, and optionally, one or more prophylactic or therapeutic agents other than an EphA2/EphrinA1 Modulator, and the use of such compositions in the treating, management, prevention and/or amelioration of an infection. Further provided by the invention are articles of manufacture and kits comprising an EphA2/EphrinA1 Modulator of the invention, and, optionally, other prophylactic or therapeutic agents (e.g., immunomodulatory agents, anti-viral agents, anti-inflammatory agents, anti-bacterial agents, anti-fungal agents, etc.).
摘要翻译：本发明提供了用于治疗，管理和/或改善感染，特别是细胞内病原体感染如病毒，细菌，原生动物或真菌感染的方法和组合物。特别地，本发明提供了用于治疗，控制，预防和/或改善感染的方法，其中EphA2的表达在受感染的细胞（例如感染的上皮细胞）中被上调，所述方法包括向受试者施用有效量的一种或更多的EphA2 / EphrinA1调节剂。根据本发明，这些方法还可以包括施用除EphA2 / EphrinA1调节剂之外的一种或多种治疗。本发明还提供包含EphA2 / EphrinA1调节剂的药物组合物，以及任选的除EphA2 / EphrinA1调节剂之外的一种或多种预防或治疗剂，以及这些组合物在治疗，管理，预防和/或改善感染。本发明进一步提供的是包含本发明的EphA2 / EphrinA1调节剂和任选的其它预防或治疗剂（例如免疫调节剂，抗病毒剂，抗炎剂，抗菌剂，抗真菌剂等）。

4. 发明申请

US20050169931A1 EphA2 as a therapeutic target for cancer 审中-公开
标题翻译： EphA2作为癌症的治疗靶点
公开(公告)号：US20050169931A1
公开(公告)日：2005-08-04
申请号：US11063101
申请日：2005-02-22
申请人： Michael Kinch , Nicole Zantek , Patrick Hein
发明人： Michael Kinch , Nicole Zantek , Patrick Hein
IPC分类号： A61K38/19 , C07K16/28 , C07K16/30 , C07K16/32 , A61K39/395 , A61K31/495 , A61K39/00
CPC分类号： C07K16/2866 , A61K38/19 , A61K2039/505 , C07K16/3069
摘要： The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor-cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
摘要翻译：本发明涉及用于治疗转移性疾病的化合物和方法。本发明的化合物对于转移性肿瘤细胞中过表达的上皮细胞酪氨酸激酶EphA2具有特异性。根据本发明使用的化合物可以提供在用于治疗转移性疾病的药物组合物中。

5. 发明申请

US20110206695A1 ANTIBODIES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF PROSTATE CANCER 审中-公开
标题翻译：用于诊断和治疗前列腺癌的抗体
公开(公告)号：US20110206695A1
公开(公告)日：2011-08-25
申请号：US13013002
申请日：2011-01-25
申请人： Manu Kohli , Michael Goldblatt , Michael Kinch
发明人： Manu Kohli , Michael Goldblatt , Michael Kinch
IPC分类号： A61K39/395 , C12Q1/70 , A61P35/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/28 , G01N33/57434 , G01N2333/15
摘要： XMRV appears to be related to both prostate cancer if it infects a male germ cell and chronic fatigue syndrome in both sexes. (If the virus does not infect a germ cell). Prostate cancer cells exhibit TSG101 on the surface only upon infection with a virus like XMRV. Antibodies to TSG101 can be effective diagnostics to identify individuals with a predisposition to prostate. They can also be used in place of current diagnostics to confirm the presence of prostate cancer. TSG101 antibodies, when administered in vivo, exhibit the ability to reduce tumor size, suppress metastatic transformation and extend survival.
摘要翻译： XMRV似乎与前列腺癌相关，如果它感染男性生殖细胞和慢性疲劳综合征两性。（如果病毒不感染生殖细胞）。前列腺癌细胞只有在感染了像XMRV这样的病毒时才在表面上显示TSG101。对TSG101的抗体可以有效地诊断以鉴别具有前列腺炎倾向的个体。它们也可以用于代替目前的诊断以确认前列腺癌的存在。 TSG101抗体在体内施用时，具有减少肿瘤大小，抑制转移转化和延长存活的能力。

6. 发明申请

US20110152343A1 PROTEASE INHIBITORS AND BROAD-SPECTRUM ANTIVIRAL 审中-公开
标题翻译：蛋白酶抑制剂和广谱抗病毒药物
公开(公告)号：US20110152343A1
公开(公告)日：2011-06-23
申请号：US12644402
申请日：2009-12-22
申请人： M. JAVAD AMAN , Michael Kinch , Sven Enterlein , Yunus Abdul
发明人： M. JAVAD AMAN , Michael Kinch , Sven Enterlein , Yunus Abdul
IPC分类号： A61K31/381 , C07D407/06 , C07D333/24 , A61K31/343 , C12Q1/70
CPC分类号： A61K31/343 , A61K31/381 , Y02A50/397
摘要： Caspace inhibition provides inhibition of viral infection across a wide collection of caspaces and viruses. Caspace inhibition, the prevention of the formation of active caspaces, can be achieved either through gene therapy, protein binding an inhibition, or through small molecule administration. Examples for small molecule inhibition allow the formation of a pharmacaphore to identify more and more active small molecules.
摘要翻译： Cas空间抑制提供对广泛的caspaces和病毒集合的病毒感染的抑制。通过基因治疗，蛋白结合抑制或通过小分子给药可以实现Cas空间抑制，预防活性胱天蛋白形成。小分子抑制的实例允许形成药物标记来鉴定越来越多的活性小分子。

7. 发明申请

US20070161064A1 Antibodies as a cancer diagnostic 审中-公开
标题翻译：抗体作为癌症诊断
公开(公告)号：US20070161064A1
公开(公告)日：2007-07-12
申请号：US11716792
申请日：2007-03-12
申请人： Michael Kinch , Nicole Zantek
发明人： Michael Kinch , Nicole Zantek
IPC分类号： G01N33/574
CPC分类号： G01N33/57496 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/57438 , Y10S436/813
摘要： Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2.
摘要翻译：提供了方法和试剂盒，用于检测和诊断转移性疾病。更具体地说，所述方法和试剂盒使用可以检测EphA2的化合物，EphA2是在转移性肿瘤细胞中过表达的特异性上皮细胞酪氨酸激酶。在一个实施方案中，化合物是能够结合EphA2表位的抗体。

8. 发明申请

US20060019899A1 EphA2 T-cell epitopes and uses therefor 有权
公开(公告)号：US20060019899A1
公开(公告)日：2006-01-26
申请号：US11233796
申请日：2005-09-23
申请人： Walter Storkus , Michael Kinch
发明人： Walter Storkus , Michael Kinch
IPC分类号： A61K38/17 , C07K14/725 , C07H21/04 , C12P21/06 , C12N5/08
CPC分类号： C07K14/4748 , A61K38/1793 , A61K39/0011 , A61K2039/55566 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , G01N33/505 , G01N33/5091 , G01N33/56966 , G01N33/56972 , G01N2333/5409 , G01N2333/57
摘要： EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

9. 发明申请

US20050153923A1 Targeted drug delivery using EphA2 or EphA4 binding moieties 审中-公开
标题翻译：使用EphA2或EphA4结合部分的靶向药物递送
公开(公告)号：US20050153923A1
公开(公告)日：2005-07-14
申请号：US11004794
申请日：2004-12-03
申请人： Michael Kinch
发明人： Michael Kinch
IPC分类号： A61K9/127 , A61K39/395 , A61K48/00
CPC分类号： C07K16/2866 , A61K39/395 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K14/52 , C07K14/715 , C07K2317/73 , C07K2317/75 , C07K2317/92 , C07K2319/30 , A61K2300/00
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, for the treatment, management, or prevention of hyperproliferative diseases, particularly cancer. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and a therapeutic or prophylactic agent that treats or prevents a hyperproliferative disease. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that treats or prevents a hyperproliferative disease, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.
摘要翻译：本发明涉及设计用于治疗，控制或预防过度增殖性细胞疾病，特别是癌症的方法和组合物。本发明的方法包括施用有效量的靶向表达Eph家族受体酪氨酸激酶（例如EphA2或EphA4）的细胞的组合物，用于治疗，控制或预防过度增殖性疾病，特别是癌症。在一个实施方案中，本发明的方法包括向受试者施用包含与递送载体连接的EphA2或EphA4靶向部分的组合物，以及治疗或预防过度增殖性疾病的一种或多种治疗或预防剂，其中所述治疗或预防试剂与输送载体可操作地相关联。在另一个实施方案中，本发明的方法包括向受试者施用包含核酸的组合物，所述核酸包含编码EphA2或EphA4靶向部分的核苷酸序列和治疗或预防过度增殖性疾病的治疗或预防剂。在另一个实施方案中，本发明的方法包括对受试者施用包含EphA2或EphA4靶向部分的组合物和包含编码治疗或预防过度增殖性疾病的药物的核苷酸序列的核酸，其中所述核酸可操作地相关联与送货车。药物组合物也由本发明提供。

10. 发明申请

US20050048550A1 EphA2 T-cell epitope agonists and uses therefor 审中-公开
标题翻译： EphA2 T细胞表位激动剂及其用途
公开(公告)号：US20050048550A1
公开(公告)日：2005-03-03
申请号：US10897711
申请日：2004-07-22
申请人： Walter Storkus , Michael Kinch
发明人： Walter Storkus , Michael Kinch
IPC分类号： A61K38/17 , C07K14/47 , C07K14/705 , G01N33/50 , G01N33/569 , C12Q1/68 , G01N33/574
CPC分类号： C07K14/4748 , A61K38/1793 , A61K39/0011 , A61K2039/55566 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , G01N33/505 , G01N33/5091 , G01N33/56966 , G01N33/56972 , G01N2333/5409 , G01N2333/57
摘要： EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
摘要翻译：本文提供EphA2 T细胞表位激动剂。激动剂包括对应于含有一个或多个T细胞表位的人EphA2蛋白的特异性片段的肽及其保守衍生物。 EphA2 T细胞表位激动剂可用于可用于确定和/或定量患者对EphA2的免疫反应性的测定中，例如ELISPOT测定。激动剂也可用于调节患者对EphA2的免疫反应性的方法，其对于过表达EphA2的癌症如肾细胞癌（RCC）具有实际作用。 EphA2激动剂也可用于通过体内或离体方法对EphA2接种患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式